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Introduction
The advent and widespread use of effective antiretroviral therapy 
(ART) to treat HIV infection has dramatically curtailed the severity 
of the neurocognitive impairment previously observed in HIV-in-
fected patients (1). However, neurological manifestations are still 
present in a number of patients (2–5). The continued, albeit ame-
liorated, presence of these neurocognitive deficiencies suggests 
that despite treatment, HIV infection may have an ongoing delete-
rious effect on the CNS. Alternatively, neurocognitive impairment 
may result from damage caused during the initial infection of the 
CNS that persists but is not progressive.
In 2015, two different groups demonstrated that the CNS has 
a functional lymphatic system that drains cerebral spinal fluid 
(CSF) into the deep cervical lymph nodes (6, 7). The discovery of a 
functional meningeal lymphatic system underscores the need for 
model systems to study the interactions between the peripheral 
immune system and the CNS during HIV infection. This is import-
ant, as the meningeal lymphatic system would represent a poten-
tial path for HIV in the brain to re-enter the periphery. This might 
be especially problematic in individuals who are infected with 
macrophage-tropic HIV, as the brain contains a large number of 
microglia (a brain-specific macrophage population), which could 
readily restart systemic HIV disease if therapy were interrupted 
or if ART-resistant viruses were present in the CNS. However, the 
majority of individuals are infected with T cell–tropic viruses (8, 
9), which have a limited ability to replicate in myeloid-derived 
cells. A study of the CSF of patients during early HIV infection 
revealed that the viruses in the CSF had an entry phenotype con-
sistent with infection of T cells only and remained T cell tropic 
through the first 2 years of infection (10). Interestingly, some 
compartmentalization was observed, in which viruses in the CSF 
were distinct from those in the blood, although these CNS-derived 
viruses retained their specificity for T cells. In a subset of patients 
with CNS virus compartmentalization, the viruses in the CSF are 
able to infect cells with a low CD4 density, suggestive of mac-
rophage tropism (11–14). This is associated with the duration of 
infection and suggests that macrophage-tropic viruses may evolve 
over time within an individual.
Although several neurological diseases are associated with 
increased numbers of T cells trafficking into the brain, such as 
herpes simplex virus infection or multiple sclerosis (15–18), there 
is evidence that deficits in the T cell compartment or prevention 
of T cell trafficking into the CNS has detrimental outcomes for 
memory and learning (19–21) and may increase disease severity 
during viral infection (West Nile virus in CCR5 deletion homozy-
gotes; ref 22). The presence of IFN-γ–expressing CD8+ T cells in 
the CSF of HIV-infected patients is associated with an increased 
risk of HIV-associated neurocognitive disorders (HAND) (23), 
suggesting a potential role for lymphocyte trafficking in neurocog-
nitive impairment. There is also evidence to suggest that a con-
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Other humanized mouse models used to study neuroHIV infection 
are created by the transplantation of human cells, either periph-
eral blood mononuclear cells (PBMCs) or CD34+ hematopoietic 
stem cells, into immunodeficient mice. HIV-infected human T 
cells were observed in the meninges and cortex of HIV-infected 
human PBMC–transplanted (hPBMC-transplanted) mice along 
with microgliosis and neuronal dropout (42). In humanized NSG 
(hNSG) mice, a CD34+ stem cell–reconstituted model, HIV RNA 
was detected in the brains of a portion of HIV-infected mice, 
although the levels of HIV DNA were below the limit of detection 
(43). In a model reconstituted with human myeloid cells but not 
T cells (myeloid-only mice [MoM]), increased numbers of macro-
phages were observed in the brains of HIV-infected animals com-
pared with numbers in uninfected controls, and infected macro-
phages were observed throughout the brain (32). While several 
types of humanized mice exist, the bone marrow/liver/thymus 
(BLT) humanized mouse model is unique, in that human T cells in 
these mice are educated in the context of HLA through implanta-
tion of human thymic tissue. The presence of HIV-infected T cells 
and macrophages was detected in the brains of BLT mice infect-
ed with an HIV-1 chimeric strain (NL4-3 envADA-IRES-GFP) (44). 
Additionally, HIV-1 pol RNA and DNA were detected in the brains 
trolled migration of T cells across the blood-brain barrier occurs 
as a part of normal neuroimmune surveillance (24–26). As the lev-
els of CD4+ and CD8+ T cells are greatly altered in immune and 
mucosal tissues during HIV infection (27–29), it will be important 
to closely monitor the possible changes in the T cell populations 
present in the CNS throughout infection. In humans, studies of 
the CNS are limited to autopsy samples, noninvasive imaging, 
and/or sampling of the CSF as a proxy for brain tissue. In order 
to address specific questions about HIV infection of the CNS in 
vivo with defined endpoints and controlled experimental design, 
animal models of infection are needed. To this effect, studies of 
HIV infection in humanized mice have been extensively used to 
answer basic questions regarding HIV transmission, pathogenesis, 
and treatment and cure strategies (30–33).
The presence of HIV and HIV-associated pathologies in the 
brain have been reported for several humanized mouse models to 
date (34, 35). In the SCID-HIVE mouse model, created by directly 
injecting HIV-infected macrophages into the brain (36, 37), pro-
found encephalitis is observed, accompanied by deficits in learn-
ing and memory (38, 39). Treatment with ART reduces patholo-
gy (38, 40, 41), suggesting that controlling viral replication is key 
to minimizing the severe neuropathology otherwise observed. 
Figure 1. Hematopoietic cells are 
present in the brains of WT and BLT 
humanized mice. (A) Flow cytometric 
analysis revealed the presence of murine 
hematopoietic cells (mCD45+) in the brains 
of BALB/c mice. Murine myeloid cells 
(mCD11b+), B cells (mCD19+), and T cells 
(mCD3ε+), including CD4+ and CD8+ T cell 
subsets, were present. (B) Representa-
tive flow cytometric plots from 2 of the 
BLT mice in Figure 2A demonstrating the 
presence of human hematopoietic cells 
(hCD45+), myeloid cells (hCD33+), B cells 
(hCD19+), and T cells (hCD3+), including 
CD4+ and CD8+ T cell subsets. (C) Pheno-
typic characterization of the human mac-
rophages in the brains of BLT mice showed 
the presence of classical (CD14+CD16–), 
intermediate (CD14+CD16+), and nonclassi-
cal (CD14dimCD16+) macrophages (gating for 
hCD45+hCD11b+CD33+ cells).
studies to human disease, the animals used in this study represent-
ed more than 50 human tissue donors and were infected with clini-
cally relevant HIV isolates and transmitted/founder (T/F) viruses, 
encompassing both T cell–tropic and macrophage-tropic strains 
(32). By minimizing blood contamination of our mouse brain sam-
ples via transcardial perfusion at necropsy, we ensured that our 
observations were tailored to examine the brain tissue rather than 
vasculature within the brain. Using T cell–only humanized mice 
(ToM), we also evaluated the role of human T cells in trafficking 
HIV to the CNS and maintaining infection in the brain in the com-
of HIV-infected BLT mice, and the levels could be reduced by ART 
(44). Recently, we demonstrated that HIV RNA levels in the brain 
can be further reduced when ART is administered in combination 
with the Tat inhibitor didehydro-cortistatin A (45).
Here, we sought to elucidate the kinetics of the cellular and 
viral changes that occur in the CNS during HIV infection using 
BLT humanized mice. To this end, we conducted a large-scale, 
cross-sectional analysis of uninfected, HIV-infected, and HIV- 
infected/ART-treated mice. We evaluated immune cell popula-
tions and HIV levels in the brain. To increase the relevance of our 
Table 1. Characteristics of the humanized mice studied
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The humanized mouse model and the total number of mice are listed for each group by figure and panel. For each experimental group, the sex of the mice (F, 
female; M, male), the level of irradiation used for preconditioning, the viruses used for exposures, the length of infection (weeks), the treatment with ART and 
the length of treatment are shown for each relevant group.
single-cell suspensions of brain tissue from perfused mice and used 
polychromatic flow cytometry to evaluate the overall abundance 
of mouse hematopoietic cells. Our results showed the presence 
of mouse myeloid, B, and T cells, including both CD4+ and CD8+ 
T cell subsets, in the brain (Figure 1A and Supplemental Figure 1; 
supplemental material available online with this article; https://doi.
org/10.1172/JCI98968DS1). For this analysis, we focused exclusive-
ly on the hematopoietic cells expressing high levels of murine CD45 
(mCD45). Since mice are naturally refractory to HIV infection and 
plete absence of human myeloid cells. This study demonstrates 
that rapid cellular and viral changes occur in the CNS following 
HIV infection and suggests a strong role for T cells in the establish-
ment and maintenance of HIV infection in the brain.
Results
The brains of BLT humanized mice are repopulated with human hema-
topoietic cells. We used BALB/c mice to determine the presence of 
hematopoietic cells in the normal brain. Specifically, we prepared 
Figure 2. Sustained reconstitution of the BLT mouse brain with human immune cells. (A) Total numbers of human hematopoietic cells, T cells, CD4+ T cells, 
CD8+ T cells, myeloid cells, and B cells in the brains of BLT mice (n = 104). Brains were harvested from BLT mice 5 to 41 week after humanization surgery, and 
flow cytometry was performed to determine the numbers of human immune cells present. Horizontal lines in A indicate the mean ± SEM. Scatter plots depict 
the total numbers of human (B) hematopoietic cells (n = 104), (C) T cells (n = 97), (D) CD4+ T cells (n = 97), (E) CD8+ T cells (n = 97), (F) myeloid cells (n = 97), 
(G) B cells (n = 94). (H) Scatter plot shows the CD4+/CD8+ ratio (n = 97) in the brain and the post-humanization surgery time points at which analysis was per-
formed. (I) Scatter plot depicts the absolute number of human CD45+ cells in the brain and the percentage of human CD45+ cells in the peripheral blood (PB) of
BLT mice (n = 103) at necropsy. A Spearman’s rank correlation test was used to analyze the data in B–I, and P values are indicated on the individual graphs.
analyzed, CD4+ T cells represented the predominant T cell subset in 
the BLT mouse brain. Additional analysis of the human myeloid cell 
population in the brain demonstrated the presence of both classical 
(CD14+CD16–) and intermediate (CD14+CD16+) macrophages (Figure 
1C). These results are consistent with those obtained from humans, 
nonhuman primates (NHPs), and WT mice and demonstrate that, in 
the absence of inflammation or any other stimulus, immune cells are 
present in the brain under normal conditions (46–51).
cannot be used for HIV research, we wanted to address whether the 
brains of BLT humanized mice are repopulated with human hemato-
poietic cells. A description of all humanized mice used for the study 
are detailed in Table 1. As in the brains of wild-type (WT) mice, we 
observed the presence of myeloid, B, and T cells, including both CD4+ 
and CD8+ T cells, in the brains of BLT mice, except that the hemato-
poietic cells in the brains of BLT mice were of human origin (Figure 
1B and Supplemental Figure 1). Similar to the BALB/c mouse brains 
Figure 3. Human immune cells are distributed throughout the brains of BLT mice. (A) The presence of human immune cells in the cerebrum (blue), brain 
stem (including midbrain, interbrain, and hindbrain, red), and cerebellum (green) of brains harvested from BLT mice was analyzed using IHC. A sagittal 
section of a BLT mouse brain was stained for hCD45. Scale bar: 1 mm. (B) Brain sections from BLT mice were stained with antibodies specific for human 
hematopoietic cells (hCD45), T cells (hCD3), and macrophages (hCD68). Scale bars: 50 μm. Original magnification, ×2 (insets). Positive cells are stained 
brown. CB, cerebellum; CC, cerebral cortex; CP, caudate putamen; HC, hippocampus; HT, hypothalamus; M, medulla; MB, midbrain, OB, olfactory bulb; P, 
pons; TH, thalamus; VS, ventral striatum.
Steady-state levels of human immune cells in the brains of BLT 
mice. We next determined the total numbers of human cells present 
in the brains of perfused BLT mice (n = 104 mice), which collec-
tively represent multiple human donor tissues (n = 43 donors). The 
total number of human immune cells present in the brains of BLT 
mice was determined using flow cytometry (Figure 2A). The num-
ber of human hematopoietic cells (hCD45+) present in the brains 
of BLT mice was consistent across time after humanization surgery 
(Figure 2B). This analysis was repeated for human T cells (Figure 
2C), CD4+ T cells (Figure 2D), CD8+ T cells (Figure 2E), myeloid 
cells (Figure 2F), and B cells (Figure 2G); no relationship between 
the weeks after humanization surgery and the absolute number of 
any cell subset was noted. Additionally, we noted no significant 
change in the CD4+/CD8+ ratio in the brain over time (Figure 2H). 
We also found no correlation between the levels of human immune 
reconstitution in the peripheral blood or brain (Figure 2I). This sug-
gests that a cellular steady state is established rapidly in the brain as 
the result of normal immune trafficking and immune surveillance 
of this tissue. We did note that an increased level of precondition-
ing irradiation (2.5 Gy versus 2.0 Gy) was associated with lower 
total numbers of human hematopoietic cells, myeloid cells, and B 
cells in the brain (P = 0.029, P = 0.011, and P = 0.049, respectively, 
Supplemental Figure 2). Additionally, brains from female BLT mice 
had higher numbers of human B cells compared with that seen in 
male BLT mice (P = 0.038, Supplemental Figure 2). The numbers of 
T cells and the CD4+/CD8+ ratio were unaffected by sex or level of 
irradiation (Supplemental Figure 2).
Distribution of human immune cells throughout the brain. We 
performed immunohistochemistry (IHC) to determine the sys-
temic distribution of human immune cells throughout the entire 
brain of BLT mice and found that human immune cells were 
present throughout the cerebrum, brain stem (consisting of the 
interbrain, midbrain and hindbrain), and cerebellum. These 
regions are outlined in Figure 3A. Specifically, we detected the 
presence of human hematopoietic cells (hCD45+), human T cells 
(hCD3+), and human macrophages (hCD68+) from the olfactory 
bulb through the base of the brain stem in the medulla (Figure 
3B), thus confirming that HIV target cells are present throughout 
the brains of BLT mice. Both CD4+ and CD8+ T cell subsets were 
present throughout the brains of BLT mice (Supplemental Figure 
3), including the olfactory bulb, cerebral cortex, caudate putamen, 
thalamus, midbrain, pons, and cerebellum. Additionally, we quan-
titated the number of hCD45+, hCD3+, and hCD68+ cells in serial 
sections of an uninfected BLT mouse brain (Table 2). While the 
distribution of human hematopoietic cells and T cells was similar 
among the 3 regions (P = 0.3897 and P = 0.0870), we detected a 
significantly greater number of human macrophages in the cere-
bellum compared with the number detected in the cerebrum (P = 
0.0264, Kruskal-Wallis test with Dunn’s post test).
Dissemination of HIV from the periphery into the brain of BLT 
mice. To determine whether HIV traffics into and can establish 
infection in the brain, we infected BLT mice with one of sever-
al CCR5-tropic isolates or a CXCR4-tropic isolate (LAI). Of the 
CCR5-tropic isolates evaluated, 3 were T/F viruses (CH040, 
THRO, and RHPA), 1 was an early-passage strain (JR-CSF), and 
1 was a laboratory-adapted macrophage-tropic virus (ADA). The 
animals were systemically infected after mucosal or parenteral 
exposure to virus, and 53 human donor tissues were represented. 
HIV DNA and/or HIV RNA levels in whole brains harvested from 
HIV-infected animals (as determined by the presence of HIV RNA 
in the peripheral blood) were quantified by real-time PCR. All 5 
viruses tested were able to establish infection in the brains of BLT 
mice. Cell-associated HIV DNA was detected in 85.1% (57 of 67) 
of the brains from HIV-infected mice (Figure 4A). We found an 
inverse correlation between the levels of HIV DNA in the brain 
and the duration of infection (P = 0.0002, Figure 4B). We detect-
ed cell-associated HIV RNA in 92.9% (104 of 112) of the brains 
from HIV-infected BLT mice (Figure 4C). To determine whether 
the route of infection (i.v., vaginal, or oral) influenced the levels 
of HIV in the brain, we analyzed 3 subsets of mice exposed via 
different routes. Our results showed no differences in the levels 
of HIV in the brain, regardless of the transmission route (all P > 
0.05, Supplemental Figure 4A). We found an inverse correlation 
between the levels of HIV RNA and the duration of infection (P 
< 0.0001, Figure 4D) and the weeks after humanization surgery 
(P = 0.0371, Supplemental Figure 4B). Importantly, we observed a 
positive association between plasma viral load (VL) and the levels 
of cell-associated HIV RNA in the brain (P < 0.0001, Figure 4E). 
To confirm productive infection in the brain, we performed IHC to 
confirm HIV antigen expression in the brains of BLT mice infected 
with either JR-CSF (Figure 4F) or CH040 (Figure 4G). We detect-
ed HIV p24+ cells in the cerebellum, thalamus, medulla, midbrain, 
and cerebral cortex. Together, these results demonstrate the abil-
ity of HIV to efficiently traffic into the brains of BLT mice and 
establish a productive and disseminated infection.
Analysis of the effect of HIV infection on human immune cell num-
bers in the brains of BLT mice. We determined the total numbers of 
human hematopoietic cells present in the brains of HIV-infected 
BLT mice (n = 47 human donor tissues represented) and compared 
them with the numbers present in the brains of uninfected mice 
(Figure 5A, left). We did not find differences in the overall number 
of human cells between infected and uninfected mice, regardless 
of the virus used for infection (Figure 5, left, and Supplemental 
Table 2. Quantitation of human hematopoietic cells  
by section in BLT mouse brains
Count per section 
(± SEM)
Count per cm2  
(± SEM)
Human hematopoietic cells  
(hCD45+)
Cerebrum 118 ± 7 668 ± 63
Brain stem 175 ± 12 769 ± 88
Cerebellum 52 ± 3 757 ± 74
Human T cells  
(hCD3+)
Cerebrum 40 ± 7 242 ± 35
Brain stem 48 ± 7 231 ± 33
Cerebellum 22 ± 3 360 ± 41
Human macrophages  
(hCD68+)
Cerebrum 69 ± 4 411 ± 19
Brain stem 110 ± 5 507 ± 23
Cerebellum 38 ± 3 578 ± 45
The numbers of hCD45+, hCD3+, and hCD68+ cells were counted in 4 serial 
sections of an uninfected BLT mouse brain and assigned to regions, as 
depicted in Figure 3A. The average number of human cells present in each 
section or per centimeter squared is reported as ± SEM.
Figure 4. HIV is present in the brains of systemically infected BLT mice. (A) HIV DNA levels in the brains of BLT mice infected with 4 different 
HIV-1 isolates (n = 20 CH040, 32 JR-CSF, 6 RHPA, and 7 THRO). (B) Scatter plot indicates the time points after infection at which HIV DNA levels 
were determined in the brains of BLT mice. (C) HIV RNA levels in the brains of mice systemically infected with HIV (n = 18 CH040, 65 JR-CSF, 4 
RHPA, 14 THRO, 6 LAI, and 5 ADA). (D) Scatter plot indicates the time points after infection at which HIV RNA levels were determined in the brains 
of BLT mice. (E) HIV RNA levels in plasma of BLT mice at the time of necropsy, when HIV RNA levels in the brain were measured (n = 112). In A–E, 
the dashed horizontal lines represent the lower limit of detection for cell-associated HIV DNA and RNA (~4 copies). In E, the dashed vertical line 
represents the lower limit of detection for the plasma VL (~688 RNA copies/ml plasma). Immunohistochemical analysis revealed the presence of 
HIV p24+ cells (brown) in the brains of BLT mice infected systemically with HIV-1 JR-CSF (F) or CH040 (G). Scale bars: 50 μm. Original magnification, 
×2 (insets). A Spearman’s rank correlation test was used for the statistical analysis of data in B, D, and E, and P values are shown in each graph. 
Horizontal lines in A and C indicate the mean ± SEM.
Figure 5. Alterations in human T cell popula-
tions in the brains of HIV-infected BLT mice. 
Total numbers of human (A) hematopoietic 
cells (hCD45+), (B) T cells, (C) CD4+ T cells, (D) 
CD8+ T cells, (E) the CD4+/CD8+ T cell ratio, and 
the numbers of (F) myeloid cells in the brains 
of HIV-infected (n = 132) or uninfected (n = 
104, from Figure 3) BLT mice were determined 
by flow cytometry. Left panels indicate the 
absolute number of cells or CD4+/CD8+ T cell 
ratio in the brains of uninfected and HIV-in-
fected BLT mice. Right panels indicate the 
absolute number of cells or CD4+/CD8+ T cell 
ratio in the brains of HIV-infected BLT mice 
and the time points after infection at which 
analysis was done. Mice infected with the same 
HIV strain are shown with the same color and 
symbol (CH040: green circles; JR-CSF: blue 
inverted triangles; RHPA: gray triangles; THRO: 
red diamonds; LAI: orange squares; ADA: black 
x). Horizontal lines indicate the mean ± SEM 
(A–F, left). *P < 0.05, **P < 0.01, and **** P < 
0.0001, by Mann-Whitney U test for compar-
ison of absolute cell numbers and CD4+/CD8+ 
T cell ratios in the brains of uninfected and 
HIV-infected BLT mice (A–F, left). The correla-
tion over time for each parameter was assessed 
using a Spearman’s rank correlation test. P 
values are shown on each graph. The dashed 
gray lines on the plots on the right represent 
the mean values for the uninfected group.
presence of HIV p24+ cells throughout the brain of an HIV-infected 
ToM, including the cerebellum, medulla, and cerebral cortex, 
showed productive infection and replication of HIV (Figure 6H). 
Fourteen human donor tissues were represented. Collectively, 
these results demonstrate that T cells are sufficient to establish and 
maintain HIV infection of the brain and that myeloid cells are not 
required to traffic HIV from the periphery into the brain.
Analysis of the impact of ART on HIV infection in the brain. Last, 
we investigated the efficacy of combination ART (cART) on HIV 
infection in the brains of BLT mice. Two triple-cART regimens were 
included in our study. The first consisted of emtricitabine, tenofo-
vir, and raltegravir (FTC/TDF/RAL), and the second consisted of 
dolutegravir, rilpivirine, and emtricitabine (DTG/RPV/FTC). Four 
of these drugs (FTC, RAL, DTG, and RPV) have especially good 
penetration into the CNS of HIV-infected individuals, as indicated 
by drug levels in the CSF (2, 56, 57). Mice were treated with cART 
for 3 to 23 weeks prior to harvesting brain tissue, and 21 human 
donor tissues were represented. cART administration resulted in 
dramatically lower or undetectable amounts of HIV DNA and HIV 
RNA in the brain (P < 0.0001 and P < 0.0001, Figure 7, A and B). 
Both regimens tested were highly effective at suppressing HIV RNA 
levels in the brain (Supplemental Figure 7, A and B). We noted no 
correlation between the VL in plasma and the low levels of resid-
ual cell–associated RNA present in the brains of ART-treated mice 
(Figure 7C and Supplemental Figure 7C). Specifically, in mice with a 
plasma VL below the limit of detection (<688 copies/ml), HIV RNA 
was still detectable in the brains of 17 of 26 (65.4%) animals. This 
suggests that, while cART effectively reduced HIV production in 
the brain, it was unable to fully suppress virus levels in this tissue. 
We also compared the absolute numbers of human hematopoietic 
cells, T cells, CD4+ T cells, CD8+ T cells, and myeloid cells in the 
brains of uninfected, HIV-infected/-untreated, and HIV-infected/
cART-treated BLT mice (Figure 7, D–I). No differences were noted 
in the total numbers of human hematopoietic cells, CD8+ T cells, 
or myeloid cells among  the 3 groups. However, we found that the 
decrease in the total number of human T cells and CD4+ T cells as 
well as the decreased CD4+/CD8+ ratio observed in HIV-infected/ 
-untreated mice (relative to uninfected animals) was restored in the 
HIV-infected/ART-treated mice. Together, these data indicate that 
the dramatic viral and cellular changes occurring in the brain as a
result of HIV infection can be significantly mitigated by cART. Also 
notable was the efficacy of ART to reduce, but not eliminate, HIV
from the brains of infected BLT mice.
Discussion
Understanding the impact of HIV infection on the brain is fun-
damentally important. It is associated with significant pathology 
and represents a potentially difficult-to-reach HIV reservoir. The 
study of HIV infection of the brain has been restricted, because 
it can only be accessed via noninvasive imaging, CSF sampling, 
and autopsy samples. Since longitudinal access to the brains of 
humans and mice is not generally possible, we conducted a large-
scale (>350 brain samples), cross-sectional analysis of the brain 
of humanized mice during HIV infection. This study includes 
multiple human donors, different viruses, and several routes of 
exposure in an attempt to represent the diversity present in the 
HIV-infected population at large.
Figure 5A). No temporal association was noted between the total 
numbers of human cells and the duration of infection (Figure 5A, 
right). We also conducted this analysis for human T cells, CD4+ T 
cells, CD8+ T cells, the CD4+/CD8+ ratio, and myeloid cells (Figure 
5, B–F, and Supplemental Figure 5, B–F). We detected significantly 
lower numbers of human T cells and human CD4+ T cells in the 
brains of HIV-infected mice (P = 0.0080 and P < 0.0001), and 
this was associated with the duration of infection (P = 0.011 and 
P < 0.0001, Figure 5, B and C). We observed an increased num-
ber of CD8+ T cells in the brains of HIV-infected mice (P = 0.0162, 
Figure 5D), although there was no temporal correlation for this 
parameter. A significantly lower CD4+/CD8+ ratio was observed in 
the brains of HIV-infected mice (P < 0.0001), and this was asso-
ciated with the duration of HIV infection (P < 0.0001, Figure 5E). 
Notably, this ratio was inverted in animals infected for as little as 
1 week. While we detected no statistically significant difference 
between the total numbers of myeloid cells in the brains of unin-
fected and HIV-infected mice, we found a positive association 
between the number of myeloid cells and the duration of infection 
(P = 0.001, Figure 5F). Additionally, we noted an inverse associa-
tion between the levels of human T cells, CD4+ T cells, and CD8+ 
T cells in the brain and the time after humanization surgery in 
HIV-infected BLT mice (Supplemental Figure 6). Overall, these 
results demonstrate that HIV infection of the brain results in a rap-
id and sustained reduction in CD4+ T cells reminiscent of the loss 
of CD4+ T cells that occurs early after infection in mucosal tissues 
like those of the gut and female reproductive tract (52–55).
T cells alone are sufficient to establish and maintain HIV infection 
in the brain. Using humanized MoM, which are devoid of human 
T cells, we demonstrated that human macrophages are sufficient 
for the seeding and persistence of HIV infection in the brain (32). 
The role of T cells in the establishment and maintenance of HIV 
infection in the brain has not yet been directly established. To 
address this important question, we used humanized T cell–only 
mice (ToM) (31). ToM are produced by implantation of human thy-
mic tissue under the kidney capsule of preconditioned NSG mice. 
Unlike BLT mice and MoM, ToM are not transplanted with autolo-
gous human CD34+ cells. Therefore, the bone marrow of ToM is not 
reconstituted with human stem cells and does not produce human 
myeloid or B cells. Rather, ToM are systemically reconstituted 
exclusively with human T cells (31). First, we established the pres-
ence of human CD4+ and CD8+ T cells in the brains of ToM using 
flow cytometric and immunohistochemical techniques (Figure 6A). 
We then determined the presence of HIV RNA in cells obtained 
from the brains of ToM infected with JR-CSF. We chose this viral 
isolate, as we previously demonstrated that it is exclusively T cell 
tropic and does not replicate in vivo in human tissue macrophages 
(32). Our results revealed the presence of HIV RNA in the brains 
of HIV-infected ToM, indicating that T cells alone are sufficient 
to establish and maintain HIV infection in the brain (Figure 6B). 
We compared the total number of human cells between uninfected 
and HIV-infected ToM. Similar to the analyses performed on BLT 
mouse brains, the cell subsets analyzed for ToM included human 
hematopoietic cells, T cells, CD4+ T cells, CD8+ T cells, and the 
CD4+/CD8+ ratio (Figure 6, C–G). Significantly lower numbers of 
CD4+ T cells and a lower CD4+/CD8+ ratio were noted in the brains 
of HIV-infected ToM compared with those in uninfected mice. The 
Figure 6. Human T cells are sufficient to establish HIV infection in the brain. (A) The numbers of human T cells in the brains of ToM were quanti-
fied using flow cytometry (n = 14), and the distribution of human cells was confirmed by staining brain sections with antibodies specific for hCD45, 
hCD3, hCD4, and hCD8 (positive cells are stained brown). (B) HIV RNA levels in the brains of ToM infected with T cell–tropic HIV-1 JR-CSF (n = 22). 
The dashed horizontal line represents the lower limit of detection for cell-associated RNA (~4 copies). The numbers of human (C) hematopoietic 
cells, (D) T cells, (E) CD4+ T cells, and (F) CD8+ T cells in the brains of uninfected (n = 14) and HIV-infected ToM (n = 26). (G) CD4+/CD8+ T cell ratio in 
the brains of uninfected (n = 14) and HIV-infected ToM (n = 26). A Mann-Whitney U test was used to analyze the data in C–G. *P < 0.05, **P < 0.01. 
Horizontal lines in A–G indicate the mean ± SEM. (H) Brain tissue sections from a systemically infected ToM were stained for HIV p24+ cells (brown). 
Scale bars: 50 μm. Original magnification, ×2 (insets).
eral blood. Interestingly, human hematopoietic cells were distrib-
uted throughout many regions of the mouse brain including the 
olfactory bulb, cerebral cortex, caudate putamen, hippocampus, 
thalamus, midbrain, pons, medulla, and cerebellum. These data 
suggest that a steady state is reached in the brains of mice and that 
the cells present in both WT and BLT humanized mice represent 
normal immune surveillance of this tissue.
Macrophage infection in the brain is a hallmark of HIV dis-
ease and has been considered key to the pathogenesis associated 
with the neurological complications often observed in infected 
patients. Using MoM, we recently demonstrated the presence of 
macrophages in the brains of these animals and that these cells 
are sufficient to establish and maintain HIV infection in this tissue 
(32). However, in some cases, viruses isolated from the CNS do not 
exhibit macrophage tropism (10). Characterization of the viral tro-
Our analysis of brains from WT mice provided a useful refer-
ence and demonstrated that during steady-state conditions, in the 
absence of any kind of inflammation or intentional disruption of 
the blood-brain barrier, hematopoietic cells normally traffic from 
the periphery and populate the brain. The presence of these cells 
in the brain is not likely due to blood contamination, since these 
mice were perfused prior to brain harvesting. Likewise, we found 
that the brains of BLT humanized mice were also reconstituted 
with human immune cells. Specifically, we were able to readily 
observe the presence of human T cells, B cells, and macrophages 
in the brains of BLT mice. These results demonstrate that, like 
endogenous mouse immune cells, human hematopoietic cells 
traffic from the periphery into the brain. The numbers of human 
hematopoietic cell populations in the brain were constant over 
time and did not correlate with the levels of human cells in periph-
Figure 7. ART effectively controls HIV-1 infection in the brain of BLT humanized mice. (A) HIV DNA and (B) HIV RNA levels in the brains of HIV-infect-
ed/-untreated (n = 52 DNA, 82 RNA) and HIV-infected/ART-treated (n = 17 DNA and 36 RNA) BLT mice. Dashed horizontal lines represent the lower limit of 
detection for cell-associated DNA and RNA (~4 copies). A Mann-Whitney U test was used to compare data in A and B. (C) Scatter plot depicts the HIV RNA 
levels in the plasma and brains of HIV-infected/ART-treated BLT mice (n = 36). Dashed vertical line represents the lower limit of detection for the plasma 
VL (~688 RNA copies/ml plasma). A Spearman’s rank correlation test was used to analyze the data in C. Absolute numbers of human (D) hematopoietic 
cells (n = 104, 101, and 44), (E) T cells (n = 97, 101, 44), (F) CD4+ T cells (n = 97, 101, and 44), (G) CD8+ T cells (n = 97, 101, and 44), (H) the CD4+/CD8+ T cell ratio 
(n = 97, 101, and 44), and (I) the numbers of human myeloid cells (n = 97, 86, and 44) in the brains of uninfected (from Figure 3), HIV-infected/-untreated 
(from Figure 6), and HIV-infected/ART-treated mice were determined by flow cytometry. In D–I, the n values for uninfected, HIV-infected/-untreated, and 
HIV-infected/ART-treated groups are indicated in parentheses from left to right. The data in D–I were analyzed using a Kruskal-Wallis test, with Dunn’s 
post test. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
T cells in the brain. Specifically, the levels of CD4+ T cells in the 
brains of ART-treated mice were significantly higher than those in 
HIV-infected/-untreated mice. In fact, the levels of CD4+ T cells 
in the brains of ART-treated mice were indistinguishable from the 
levels detected in noninfected mice. As CD4+ T cells in the brain 
are thought to support learning behaviors (20, 21), restoration of 
the number of these cells could benefit the neurocognitive func-
tioning of HIV-infected individuals. These results demonstrate 
that ART controls HIV infection in the brain and restores CD4+ 
T cells to normal levels. We also show a persistence of HIV in the 
brains of treated animals, which will allow us to determine wheth-
er therapies designed to affect the persistent HIV reservoir sys-
temically will have an impact on persistence in the CNS.
As with any study conducted using relevant animal models, 
there are several limitations to this work. One important limita-
tion of this study is that we were unable to evaluate the potential 
contribution of microglia to the propagation or maintenance of 
infection in HIV-infected BLT humanized mice with or without 
ART treatment. Fate-mapping studies have revealed that microg-
lia are derived from early precursor cells present in the yolk sac 
(58, 60, 61), suggesting that human microglial cells might not 
be recapitulated in any current humanized mouse model. The 
presence of human microglia would be of importance when eval-
uating macrophage-tropic isolates, as they could support more 
robust viral replication and induce profound pathology in the 
surrounding tissue. However, the lack of human microglia should 
not affect the results obtained with T cell–tropic viruses. Another 
limitation of this and other humanized mouse models is the fact 
that the remaining cells present in the brain are of murine, not 
human, origin. However, the critical interactions between HIV 
proteins like Tat and Env have been shown to act on murine brain 
cells and induce pathological sequelae, even in the absence of 
human hematopoietic cells (62–64). Finally, the overall lifespan 
of mice is relatively short compared with that of humans. There-
fore, we are unable to follow our animals over several years after 
infection. In humans, the transition of T cell–tropic CNS viruses 
to a macrophage-tropic entry phenotype generally corresponds 
with a longer time of infection, allowing for extensive replica-
tion within this compartment that leads to viral evolution (10, 
13). The extent to which any humanized mouse model is able to 
recapitulate the full complexity of neuroAIDS has yet to be deter-
mined. However, the present study demonstrated CD4+ T cell 
depletion, a hallmark of HIV infection and disease progression, 
and the ability of ART to mitigate this depletion.
The human brain is an important site of HIV infection where 
virus can replicate and possibly seed long-lasting reservoirs. Our 
studies indicate that both T cells and macrophages (32) can be suc-
cessfully and independently infected in this organ. The notion that 
macrophages alone are responsible for the seeding of HIV infec-
tion in the brain is not supported by the presence of T cell–tropic 
viruses in the CSF of patients (10) or in the brains of BLT mice and 
ToM. Even though infection of the brain can take place shortly 
after exposure, ART dramatically reduces viremia and CD4+ T 
cell depletion in the brain, which is consistent with the significant 
benefits of early treatment intervention. One issue that remains 
to be addressed is whether HIV-infected cells in the brain (mac-
rophages, microglia, or T cells) represent persistent reservoirs 
pism in CSF samples from 24 patients revealed the presence of R5 
T cell–tropic viruses, with little or no ability to infect macrophages, 
suggesting that in these specific cases, the source of virus in the 
CNS was infected T cells (58). To determine whether infection of 
human T cells in the brain is dependent on the presence or traffick-
ing of human macrophages, we exposed both BLT mice and ToM to 
HIV, which allowed us to examine T cell infection of the CNS in the 
presence or absence of human macrophages. ToM are devoid of 
human myeloid cells but are systemically repopulated with human 
T cells (31), thus providing a unique opportunity to investigate HIV 
infection in the brain in the absence of human macrophages. Our 
results demonstrate that all six HIV strains tested (five R5-tropic 
and one X4-tropic), regardless of the route of exposure (vaginal, 
oral, or parenteral), efficiently established infection in the brains 
of BLT mice. Evidence of HIV infection and replication in human T 
cells in the brains of BLT mice are supported by the fact that infec-
tion was established by three HIV-1 T cell–tropic isolates (JR-CSF, 
THRO, and RHPA) that do not replicate in macrophages (32). HIV 
was also readily found in the brains of ToM, demonstrating that T 
cells, in the absence of human macrophages, are sufficient for both 
the trafficking and establishment of HIV infection in this tissue.
HIV infection in the brains of BLT mice permitted the eval-
uation of its effect on human T cells and macrophages during the 
course of infection. HIV infection resulted in a rapid and sustained 
drop in the levels of human CD4+ T cells in the brain. The rapid and 
profound reduction in CD4+ T cells in the brain is highly reminis-
cent of what is observed in mucosal tissues like the those of the gut 
and female reproductive tract (52–55) and indicates that HIV can 
inflict damage to the immune system in the brain early after infec-
tion. Consistent with the progressive loss of human CD4+ T cells in 
the brain, we documented an inverse correlation between the dura-
tion of infection and HIV RNA and HIV DNA levels in the brain, 
suggesting that during the initial establishment of infection, when 
viremia is highest, high levels of virus are also present in the brain. 
Interestingly, consistent with our previous results in MoM, we did 
not notice a reduction in the levels of myeloid cells in the brains of 
HIV-infected BLT mice (32). Rather, we noticed an increase in the 
number of myeloid cells in the brains of infected mice over time. In 
autopsy samples from HIV-infected patients, the diffuse presence 
of CD68+ and CD8+ cells was noted in the deeper midline and mesi-
al temporal structures of the brain, including the midbrain, pons, 
medulla, thalamus, hippocampus, and cerebellum (59). When 
HIV-associated dementia was also present, robust numbers of HIV 
p24+ cells were also noted in these regions. In our mice, we detected 
the presence of human target cells in these particular regions and 
the presence of virus and productively infected cells in the mid-
brain, medulla, thalamus, and cerebellum of mice exposed to HIV-1 
JR-CSF (T cell–tropic) or CH040 (macrophage-tropic).
ART has significantly decreased the incidence and severity 
of neurological complications associated with HIV infection. It 
was therefore important to determine the effect of ART on HIV 
replication and CD4+ T cell depletion in the brains of BLT mice. 
Our results show that ART efficiently suppressed HIV RNA and 
HIV DNA levels in the brain. However, we did not observe a cor-
relation between plasma VL and HIV RNA levels in the brains of 
HIV-infected/ART-treated mice. Remarkably, we found that ART 
treatment had a significant (P < 0.001) effect on the levels of CD4+ 
according to the portion of the brain processed, stained, and analyzed. 
The gating scheme for all samples was live cells (forward scatter/side 
scatter [FSC/SSC]), and then either mCD45++ or hCD45+ cells.
Immunohistochemical analysis of brains. Brains for immunohisto-
chemical analysis were harvested from BLT mice and fixed in 4% para-
formaldehyde for 16 to 24 hours at 4°C. Whole brains were separated 
into half brains at the midline and cut into sagittal sections starting at 
the midline. Samples were then embedded in paraffin, cut into 5-μm 
sections, and mounted onto poly-L-lysine–coated glass slides. Follow-
ing paraffin removal, antigen retrieval (DIVA Decloaker, Biocare Med-
ical, catalog DV2004), and blocking of nonspecific Ig-binding sites 
(Background Sniper, Biocare Medical), tissue sections were stained 
with primary antibodies overnight at 4°C, probed with a biotin-free 
HRP-polymer system (MACH3 Mouse HRP-Polymer Detection, Bio-
care Medical), and developed with diaminobenzidine (ImmPact DAB 
Peroxidase Substrate, Vector Laboratories). All tissue sections were 
counterstained with hematoxylin. Primary antibodies directed against 
CD45 LCA (2B11 and PD7/26, Dako); CD3 (Sp7, Thermo Fisher Scien-
tific); CD4 (SP35, Genway); CD8 (C8/144B, Dako); CD20 (L26, Bio-
care Medical); and CD68 (KP1, Dako) were used to identify the types 
of human cells present in the brains of humanized mice. HIV-infected 
cells were detected with an antibody directed against HIV p24 Gag 
(Kal-1, Dako). As a control, tissue sections were stained with either 
mouse IgG1k (Dako), mouse Ig2ak (Dako), or rabbit IgG (Dako) neg-
ative control antibodies. Light microscopy images were taken using 
an Aperio ScanScope XT (Leica Biosystems) with the assistance of 
the Translational Pathology Laboratory at UNC-CH. Representative 
images were acquired using Aperio ImageScope software.
HIV-1 analysis and exposures. PCR analysis for HIV gag was per-
formed by first preparing genomic DNA from MNCs using QIAamp DNA 
blood mini columns (QIAGEN) according to the manufacturer’s proto-
col. HIV RNA levels were monitored using a 1-step reverse transcriptase 
real-time PCR assay (TaqMan Assays-by-Design, ABI) according to the 
manufacturer’s instructions (with primers 5′-CATGTTTTCAGCAT-
TATCAGAAGGA-3′ and 5′-TGCTTGATGTCCCCCCACT-3′). Stocks 
of HIV-1 (JR-CSF, RHPA, THRO, LAI, ADA, and CH040) were prepared 
and titered as previously described (32). Briefly, virus supernatants were 
prepared via transient transfection of 293T cells and were titered using 
TZM-bl cells (an indicator cell line) as previously described (33). Ani-
mals were exposed i.v., rectally, vaginally, or orally to the various viral 
isolates. Inoculum doses (in tissue culture infectious units) by route of 
exposure were up to: 9 × 104 (i.v.), 5 × 106 (rectal), 3.6 × 105 (vaginal), and 
1.4 × 106 (oral) (30, 33, 52, 68, 69).
Antiretroviral treatment of humanized mice. For HIV treatment, 
we used 2 ART regimens. The first, FTC/TDF/RAL, is a previously 
described triple-combination of drugs that we have shown to be effec-
tive at suppressing the VL in ToM and BLT mice (30, 31, 52, 68). This 
regimen was administered by either daily injection or via a formulated 
rodent chow. The dosage of the injectable formulation was 212 mg/kg 
emtricitabine, 205 mg/kg tenofovir disoproxil fumarate, and 56 mg/
kg raltegravir (provided by Merck). The formulated FTC/TDF/RAL 
chow contained 1,500 mg emtricitabine, 1,560 mg tenofovir disoprox-
il fumarate, and 600 mg raltegravir per kilogram of pellets (Research 
Diets). The second regimen, DTG/RPV/FTC, was also a triple-com-
bination therapy administered by daily s.c. injection. The dosage of 
this injectable formulation was 213 mg/kg emtricitabine, 8.8 mg/kg 
rilpivirine, and 17.6 mg/kg dolutegravir.
capable of reigniting infection upon reactivation of virus with-
in the CNS and, as such, should be targeted by future HIV cure 
approaches. Recent evidence in SIV-infected, ART-treated NHPs 
showed the presence of replication-competent virus in brain mac-
rophages, suggesting that the brain can be a source of virus, despite 
treatment (65). However, it remains to be determined whether this 
is true of HIV infection in the human brain. Models like the BLT 
mouse, MoM, and ToM (31, 32, 66, 67) provide useful tools for 
addressing many questions regarding HIV infection of the CNS.
Methods
Generation of humanized mice. Humanized BLT mice and ToM were 
prepared by implanting human thymus and liver tissue into precondi-
tioned 8- to 12-week-old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice 
(The Jackson Laboratory) (30, 31, 33). The thymus and liver implants 
consisted of a 1- to 2-mm piece of liver tissue sandwiched between 2 
pieces of autologous thymus that were placed under the left kidney 
capsule (Advanced Bioscience Resources). BLT mice were also given 
an autologous stem cell transplant containing approximately 3.5 × 105 
CD34+ cells (cells isolated from the liver). The reconstitution of mice 
with human immune cells was monitored over time by polychromat-
ic flow cytometric analysis of human CD45+ cells in peripheral blood, 
as previously described (30, 33). Whole peripheral blood was stained 
with antibodies, red blood cells were lysed, and the remaining cells 
were washed and fixed using a 1% paraformaldehyde solution.
Brain harvesting from mice. Transcardial perfusion with 20 ml of 
room-temperature PBS was performed at necropsy to minimize blood 
contamination within the brain. Heads were separated from the spine 
at the C1 vertebrate. The entire brain was collected, including the cho-
roid plexus and brainstem, but the meninges were not included. All 
mice in Figures 1–6 were perfused; however, only 29 of 47 (61.7%) of the 
ART-treated animals from Figure 7 were perfused. These animals were 
part of another study that required that the animals not be perfused. 
Brains were collected into 10 ml HBSS and processed as described previ-
ously (32). Whole brains or half brains (split into hemispheres, along the 
midline) were passed through a 70-μm strainer, and mononuclear cells 
(MNCs) were isolated using a Percoll density centrifugation gradient. An 
average of 2 × 105 MNCs were purified from whole-brain samples.
Flow cytometric analysis. Antibodies for flow cytometric analysis 
were purchased from BD Biosciences or BioLegend. The antibody 
panel used to analyze cells isolated from nonhumanized (BALB/c) 
mice included antibodies directed against mCD45 (APC, BD, catalog 
559864 or APC-Cy7, BD, catalog 557659); mCD3e (PE-Cy7, BD, cata-
log 552774); mCD19 (PE-Cy7, BD, catalog 553786); and mouse/human 
CD11b (PE, BioLegend, catalog 101207). The antibody panel used to 
analyze cells isolated from humanized mice included antibodies direct-
ed against hCD45 (APC, BD, catalog 555485 or APC-Cy7, BD, catalog 
557833); hCD3 (FITC, BD, catalog 555339); hCD4 (APC-H7, BD, cat-
alog 560158); hCD8 (PerCP, BD, catalog 347314); hCD19 (PE-Cy7, 
BD, catalog 557835); hCD11b (PE, BD, catalog 555388 or APC, catalog 
340937); hCD14 (FITC, BD, catalog 555397); hCD16 (PE-Cy7, BD, cat-
alog 557744); and/or hCD33 (PE, BD, catalog 340679). Live cells were 
distinguished by their forward and side scatter profiles. Flow cytomet-
ric data were collected on either a BD FACSCanto or a BD LSRFortessa 
flow cytometer and analyzed using BD FACSDiva software (version 
6.1.3). The count/brain was calculated on the basis of the total num-
ber of events for flow cytometric analysis in each sample and scaled 
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